Cu-64 — Diagnose
Maps the precise location and extent of cancer through PET imaging.
Next-generation oncology products
In vitro and in vivo products that address the demand for precision theranostics in cancer diagnosis and targeted cancer therapy — all powered by NV-VPAC1.
The NV-VPAC1 Platform
One molecule, three applications
NV-VPAC1 binds to the overexpression of VPAC1 receptors for the in vitro or in vivo diagnosis of cancer cells — providing binary endpoints for diagnosis and subsequent treatment of numerous cancer indications. Breast cancer, particularly triple-negative breast cancer (TNBC), is NuView's lead clinical focus.
In Vitro Diagnostics
Detect cancer in biofluids — no surgical biopsy
NuView's in vitro diagnostic lab assay pairs our small molecule with a fluorophore to accurately detect cancer cells in biofluids. It avoids genetic tests and eliminates the discomfort of surgical biopsy and unnecessary medical procedures.
- Liquid biopsy approach using blood, urine and saliva
- Avoids invasive, uncomfortable procedures
- High accuracy detection of shed cancer cells
In Vivo Diagnostics
Precision PET imaging with Copper-64
NuView's diagnostic imaging compound for Positron Emission Tomography (PET / PET-CT / PET-MRI) utilizes a Copper-64 (Cu-64) positron emitter to localize all sites of GPCRs.
NV-VPAC1 is the key to imaging the precise location and extent of tumor metastasis — giving clinicians a clear, targeted view of the disease.
Theranostics
Targeted Copper Theranostics (TCT)
Our disruptive platform pairs Copper-64 (Cu-64) and Copper-67 (Cu-67) for mapping out cancer in the body and treating it — a highly productive, scalable, and cost-effective way to expand precision theranostics into the global oncology market.
Cu-67 — Treat
Delivers targeted therapy by coupling cytotoxic agents to NV-VPAC1.
Patient-Centric
High accuracy and precision with supply and logistical advantages.
The Broader Platform
Beyond imaging: NuView's other NV-VPAC1 programs
The Cu-64 / Cu-67 theranostic for triple-negative breast cancer is NuView's lead program. The same VPAC1 receptor biology powers a separate pipeline of diagnostic applications, developed alongside the lead asset.
Liquid biopsy
An NV-VPAC1 peptide labeled with a fluorophore lights up cancer cells shed into biofluids such as urine — a radiation-free way to confirm cancer by optical imaging.
Lateral-flow strip test
A rapid, low-cost strip-pad format of the liquid-biopsy assay under development — bringing NV-VPAC1 cancer confirmation to the point of care.
Binary confirmation
One receptor read two ways — liquid biopsy in the lab and Cu-64 PET in the body — for high-confidence confirmation of VPAC1-positive disease.
NuView's clinical pipeline also includes rare indications such as brain (glioblastoma) and pancreatic cancers. All NuView programs are in clinical development and not approved by the FDA.
Technology Pipeline
VPAC1 receptor overexpression across cancers
Independent evaluation of VPAC1 receptor overexpression in human pathological samples shows broad applicability across cancer indications.
Breast carcinoma100%
Prostate carcinoma100%
Meningioma100%
Urinary bladder carcinoma100%
Endometrial carcinoma100%
Paraganglioma100%
Colorectal carcinoma96%
Pheochromocytoma72%
Leiomyoma66%
Pancreatic carcinoma65%
Lung carcinoma58%
Non-Hodgkin's lymphoma58%
Gastric carcinoma54%
Liver carcinoma49%
Source: independent evaluation of VPAC1 receptor overexpression in human pathological samples, as referenced on the NuView Life Sciences technology pipeline.
Interested in our pipeline or a partnership?
Tell us what you're looking for and our team will follow up.
Contact Us